Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)

Summary

Childhood fever is a prevalent problem. Most febrile children who visit hospital improve without treatment, but a minority require treatment, and a few will have severe disease. The investigators want to improve the diagnosis and management of febrile children by developing tests to distinguish between bacterial and viral disease so that antibiotic treatment can be initiated promptly and only when required. Judicious and prudent use of antibiotics will reduce the likelihood of developing resistant organisms and save treatment costs.

The investigators will prospectively recruit acutely febrile children presenting to hospital, collecting research samples for validation of biomarkers, in combination with clinical phenotypic markers and host genetic markers (BIVA-studies).

Any febrile child newborn to under 18 presenting to hospital will be eligible for recruitment. The study will last 5 years.

Conditions

• Fever
• Infection
• Inflammation

Interventions

DIAGNOSTIC_TEST

Validation of biomarker

Sponsors & Collaborators

• London School of Hygiene and Tropical Medicine

  collaborator OTHER

• University of Liverpool

  collaborator OTHER

• University of Newcastle Upon-Tyne

  collaborator OTHER

• Erasmus Medical Center

  collaborator OTHER

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  collaborator OTHER

• National and Kapodistrian University of Athens

  collaborator OTHER

• Stichting Katholieke Universiteit

  collaborator OTHER

• University of Graz

  collaborator OTHER

• University of Ljubljana

  collaborator OTHER

• Riga Stradins University

  collaborator OTHER

• Medical Research Council Unit, The Gambia

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  collaborator OTHER

• University of Bern

  collaborator OTHER

• University of Oxford

  collaborator OTHER

• University Hospital, Paris

  collaborator OTHER

• University of Santiago de Compostela

  collaborator OTHER

• Servicio Gallego de Salud

  collaborator OTHER_GOV

• BioMérieux

  collaborator INDUSTRY

• Micropathology Ltd, University of Warwick

  collaborator INDUSTRY

• Imperial College London

  lead OTHER

Principal Investigators

• Michael Levin · Imperial College London

Eligibility

Max Age

17 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2016-06-02

Primary Completion

2021-01-25

Completion

2021-12-31

Countries

• United Kingdom

Study Locations